Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility

19 Aug 2014

Abstract excerpt

The epidermal growth factor receptor (EGFR) is a member of the ErbB family that can promote the migration and proliferation of breast cancer cells. Therapies that target EGFR can promote the dimerization of EGFR with other ErbB receptors, which is associated with the development of drug resistance. Understanding how interactions among ErbB receptors alter EGFR biology could provide avenues for improving cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to HER2/EGFR in Cancer Research
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25140053
DOI: 10.1126/scisignal.2005157

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motilityPMID 25140053Read ↗

Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association.Semantic proximity Read ↗

Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis.Semantic proximity Read ↗

Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failureSemantic proximity Read ↗

A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and MetastasisSemantic proximity Read ↗

Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism.Semantic proximity Read ↗

Structure–function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targetingSemantic proximity Read ↗

E3 ligase-inactivation rewires CBL interactome to elicit oncogenesis by hijacking RTK-CBL-CIN85 axis.Semantic proximity Read ↗

The c-erbB-2 Protein in Oncogenesis: Molecular Structure to Molecular EpidemiologySemantic proximity Read ↗

MET and ERBB2 Are Coexpressed in ERBB2+ Breast Cancer and Contribute to Innate ResistanceSemantic proximity Read ↗

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.Semantic proximity Read ↗

Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo.Semantic proximity Read ↗

Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological FunctionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.